Moderna Inc. stock (US60770K1034): Shares surge on positive flu vaccine data and regulatory filings

Moderna Inc. stock jumps more than 12% after positive Phase 3 data for its mRNA flu vaccine and new regulatory filings in the U.S., EU, Canada and Australia.

Moderna Inc. shares surged more than 12% intraday on Friday, May 8, 2026, to around 54.65 USD on Nasdaq, according to MarketBeat as of May 8, 2026. The move followed the release of peer?reviewed Phase 3 data showing that Moderna’s mRNA?1010 influenza vaccine outperformed standard?dose flu vaccines in adults aged 50 and older, according to the same source. The company has also filed for approval in the United States, the European Union, Canada and Australia, with a U.S. Food and Drug Administration decision expected later this year, which could materially expand Moderna’s revenue beyond its COVID?19 vaccine business.

By the close of trading on May 8, 2026, Moderna’s stock stood at about 54.35 USD, up roughly 12.3% from the prior close, according to Barchart as of May 8, 2026. The rally lifted the stock close to its 52?week high of 57.80 USD reached in March 2026 and extended a year?to?date gain of about 76.6%, the same report notes. Despite the strong momentum, the company’s market capitalization remains below 25 billion USD, reflecting ongoing questions about long?term growth and profitability beyond the pandemic?era spike.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Moderna Inc.
• Sector/industry: Biotechnology / pharmaceuticals
• Headquarters/country: Cambridge, Massachusetts, United States
• Core markets: United States, Europe, Canada, Australia and other global markets
• Key revenue drivers: mRNA?based vaccines (COVID?19, influenza, other infectious diseases and oncology candidates)
• Home exchange/listing venue: Nasdaq Global Select Market (ticker: MRNA)
• Trading currency: USD

Moderna Inc.: core business model

Moderna Inc. is a biotechnology company focused on developing and commercializing messenger RNA (mRNA)?based vaccines and therapeutics. The company’s platform uses synthetic mRNA to instruct cells to produce specific proteins, which can then trigger an immune response or correct a genetic defect. Moderna’s initial commercial success came from its COVID?19 vaccine, which became a major global supplier during the pandemic and established the company as a leading player in mRNA technology.

Since the pandemic, Moderna has sought to broaden its pipeline beyond COVID?19, targeting seasonal influenza, other respiratory viruses, hantavirus and oncology indications. The company’s business model relies on high?margin vaccine sales, partnerships with governments and health systems, and potential future royalties or milestone payments from collaborations. Moderna’s strategy emphasizes rapid development cycles and scalable manufacturing, which can support quick responses to emerging pathogens but also expose the company to demand volatility once emergency?use periods end.

Main revenue and product drivers for Moderna Inc.

Moderna’s primary revenue driver remains its COVID?19 vaccine portfolio, which generated substantial sales during 2020–2023 but has since declined as global demand normalized. The company has reported year?over?year revenue growth of about 260% in recent quarters, according to MarketBeat as of May 8, 2026, reflecting both residual COVID?19 demand and early contributions from newer products. However, earnings per share have remained negative, with a reported loss of about 3.40 USD per share versus an expected loss of 3.02 USD, highlighting ongoing profitability challenges.

The mRNA?1010 influenza vaccine is now emerging as a key potential growth driver. Positive Phase 3 data in adults 50 and older, combined with regulatory filings in the United States, the European Union, Canada and Australia, position Moderna to compete in the seasonal flu vaccine market, which is significantly larger and more stable than the pandemic?driven COVID?19 segment. Additional pipeline candidates, including a hantavirus vaccine that showed strong immune responses and good tolerability in a Phase 1 trial, according to Barchart as of May 8, 2026, could further diversify Moderna’s revenue base if they advance through later?stage trials and gain approval.

Why Moderna Inc. matters for US investors

For US investors, Moderna Inc. represents exposure to a leading mRNA platform with potential applications across infectious diseases and oncology. The company’s Nasdaq listing and predominantly USD?denominated trading make it directly accessible to retail and institutional investors in the United States. Moderna’s pipeline progress, particularly in influenza and other respiratory vaccines, could influence broader biotech and healthcare sector sentiment, especially if the company demonstrates the ability to convert clinical success into sustainable revenue streams.

At the same time, Moderna’s stock remains highly sensitive to regulatory decisions, clinical trial outcomes and macro factors such as vaccine demand and government procurement policies. The recent 12% intraday jump on positive flu data illustrates how single?event catalysts can drive sharp moves, underscoring the importance of risk management for investors considering exposure to the stock. US investors should also monitor valuation metrics, including a negative price?to?earnings ratio and relatively high beta, which signal elevated volatility and uncertainty about long?term earnings power.

Conclusion

Moderna Inc. stock has rallied sharply after positive Phase 3 data for its mRNA?1010 influenza vaccine and new regulatory filings in the United States, the European Union, Canada and Australia, according to MarketBeat as of May 8, 2026 and Barchart as of May 8, 2026. The move highlights investor optimism about the company’s ability to expand beyond COVID?19 vaccines into larger, more stable markets such as seasonal influenza. However, Moderna continues to report net losses and faces execution and regulatory risks that could weigh on future performance.

Analyst sentiment on Moderna is mixed, with a consensus rating leaning toward “Reduce” and an average price target below the current share price, according to MarketBeat as of May 8, 2026. This divergence between recent price action and fundamental views underscores the speculative nature of the current rally. For US investors, Moderna offers high?beta exposure to mRNA innovation but also requires careful consideration of valuation, pipeline risk and the company’s path to sustained profitability.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.